Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
20.03.2023 - Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to $550 million of the company’s common stock before the end of 2023. The timing and amount of any share repurchases under the .
- ADU-1805 is a potential best-in-class monoclonal antibody targeting SIRPa to block the SIRPa-CD47 checkpoint - - Phase 1 study of ADU-1805 as a single agent and in a combination regimen in advanced
Exelixis (EXEL) and Bristol Myers Squibb (BMY) Reports Strong Results from Phase 3 CheckMate-9ER Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Approval is based on COSMIC-311 trial, in which CABOMETYX demonstrated significant improvement in progression-free survival versus placebo - Exelixis, Inc. (Nasdaq: EXEL) today announced that